Connecting Patients to Clinical Trials

Developing innovative technologies and media for facilitating patient recruitment

TrialX enables...


such as Cinda to find trials for herself and her loved ones

Search Trials


such as Jennifer to complete her clinical trial recruitment on time

Upload Your Trial


such as the Cleveland Clinic to create a centralized trial listing and recruitment tool

Learn More


such as the MMRF to create awareness for research and trials

Learn More

Why customers love TrialX.

Innovative Technology

Developed using an award winning semantic technology that matches patients to trials using their full-clinical record and clinical trial inclusion/exclusion criteria. Recently, we developed another novel interactive question/answering technology (winner of the 2011 NCI/Health 2.0 Developer Challenge) that guides and connects patients to research site using live calls

Great User Experience

At TrialX, we develop tools that we'd like to use. We continually refine the user interface and the flow to make it even easier for our customers to do their tasks effectively.

Customer Service

We Listen. We listen to what our customers say and often we fix/add features even before they tell us. The secret sauce of our awesome customer service is that we also "listen" to DATA. We mine access logs, error logs to solve problems before they arise (sort of like the Minory Report!)

I have been very pleased with the recruitment effort of TrialX for my research studies. They have been very diligent in finding qualified subjects in a reasonable time frame. I would definitely recommend their services to clinical research sites.

Dr. Arthur Waldbaum MD
  • Looking for a last minute Holiday gift idea?  Plan a trip to join us for the second annual Pat’s Myeloma Beach Party, March 20-22nd on Fernandina Beach.  The cost is reasonable: only $20 per person which includes FIVE meals and an amazing swag bag full of expensive goodies.  Admission to all wellness and myeloma related […]
  • My former myeloma specialist, Dr. Melissa Alsina, is running an unusual clinical trial for newly diagnosed patients, featuring an auto stem cell transplant, followed by an allo (donor) transplant.  Tandem auto/allo transplants are considered experimental and risky, especially for new patients.  However, Dr. Alsina and her colleagues hope to have developed a way to help […]
  • I often label myeloma related broadcasts as “must listen.”  Last night’s Cure Talks Myeloma Panel discussion with myeloma specialist,  Dr.Parameswaran  Hari, was a “must listen squared!  I didn’t mean to dominate the discussion, but following a brief review of ASH related data, Dr. Hari spent over a half hour answering my questions about Total Therapy […]
  • I admit it; I watch the daytime soap opera, Young and the Restless.  Actually I don’t “watch it.”  I rarely sit still long enough to watch anything.  But I record the episodes and play them back when I’m doing dishes or folding laundry.  That’s right; with Pattie working full time, call me “Mr. Mom.” Anyway, […]
  • The Hospital I go to when my asthma gets really bad recently upgraded their electronic charting and patient care computer systems. They’re using the EPIC system, which includes a patient portal via the web. It’s pretty cool because things like labs and xray results are made available to patient almost as soon as they’re available […]
  • Don’t miss this month’s Cure Talks broadcast Wednesday afternoon, featuring young, up-and-coming myeloma specialist, Dr. Paramaswaran Hari. My good friend and companion at this year’s ASH, Gary Petersen, wrote an enthusiastic blog post last week promoting tomorrow’s on-air discussion with Dr. Hari, and sharing his thoughts about the untapped potential of the new CrowdCare Foundation […]
  • [...]
  • I hinted about how many amazing topics I have to write about following the American Society of Hematology (ASH) annual meetings last week.  I’m hopeful about research initiatives I heard; my spirits buoyed by seeing so many old friends and supporters–and I plan to write about it all. But the primary reason for my trip?  […]
  • Here’s exciting news about a completely different type of immunotherapy: individually modified T Cells. According to Dr. June, this T-cell therapy works against multiple myeloma, too: Therapeutic Efficacy of Chimeric Antigen Receptor T Cells Carl H. June, MD Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Translational Research Program, Abramson Family […]
  • The year following my stem cell transplant, I wrote a 300 page book, Stem Cell Transplants from a Patient’s Perspective.  I published a second edition this spring.  It’s full of tips and interviews with other transplant patients. The first 20+ pages provide background about the different type of transplants, how they work and what they […]
  • I attended ASH, courtesy of my new friends at Myeloma Crowd Foundation.  I spent a lot of time with the fun,–sometimes crazy and never dull–Gary Peterson.  Gary and I volunteered to join a new Patient Advisory Board, designed to help Myeloma Crowd identify the best of the best myeloma clinical trials, and then to work […]
  • Most people will tell you Im one of the nicest, caring people you’ll ever meet. But make no mistake, when Im recovering from a bad asthma exacerbation, I can become an obnoxious asshole… and usually do. I get anxious, I get irritable, I get angry and nasty all at the same time. I snap at […]
  • I  wrote about an experimental drug, BT-062, after last year’s ASH. The drug still seems to be flying below the radar. I’m going to find out why; numbers look really good! Here’s a link to my post from meetings in New Orleans last year: Best of ASH (Part Four)   And here’s the latest from […]
  • [...]
  • I’m going to be continuing my series with tips to help deal with chemotherapy side effects when the dust clears after ASH.  But speaking with a number of myeloma survivors in San Francisco got me thinking.  What is the cumulative effect of myeloma therapy on our bodies? Sometimes it comes on slowly, so maybe we […]
  • I had the good fortune of dining with Dr. Noopur Raje last evening here in San Francisco.  We discussed several of the studies she reviews in this article: New Developments in Multiple Myeloma Dr. Noopur Raje – December 8, 2014 As part of our coverage of the 56th American Society of Hematology (ASH) Annual […]
  • As promised, here’s an update on the two hottest immunotherapies at ASH this year: daratumumab and SAR650984. Here are excerpts from Silas Inman’s article, Anti-CD38 Antibodies Highly Effective in Multiple Myeloma, on Sunday: Anti-CD38 monoclonal antibodies continue to demonstrate promise across a variety of settings, generating excitement that a new treatment paradigm could be on […]
  • “Copycat therapies?”  That may be a bit harsh.  I’m referring to a seemingly endless stream of drugs under development from the same class. Velcade, the original proteasome inhibitor, is a tried and true standard.  Then Onyx Pharmaceuticals worked tirelessly to develop a competing drug from the same class, Kyprolis, as quickly as possible.    Planning […]
  • It’s the holiday season. One of the things I look forward to most in December? Spending time at ASH. This will be the sixth consecutive year that I’m attending the American Society of Hematology annual meeting. While most people are getting in the holiday spirit, I’m rushing for miles through crowded concourses and sitting in […]
  • ASH news is flying around the internet!  Most is anticipatory; early teasers of technical presentations still to come.  Most myeloma related news here pops Sunday and Monday.  That’s why I didn’t arrive until today. Here’s something interesting.  I hadn’t heard much about a preclinical drug, ACY-1215 since I wrote several posts about it in 2013.  […]